NaPro Announces Formation of Oncology Scientific Advisory Board
April 27 2004 - 8:30AM
PR Newswire (US)
NaPro Announces Formation of Oncology Scientific Advisory Board
BOULDER, Colo., April 27 /PRNewswire-FirstCall/ -- NaPro
BioTherapeutics, Inc. today announced the formation of an Oncology
Scientific Advisory Board to advise the company on the clinical
development of its proprietary new drug candidates for the
treatment of cancer. Paul A. Bunn, Jr., M.D., a member of the
Company's Scientific Advisory Board, will serve as the Chair of the
Oncology Scientific Advisory Board. "Our development team at NaPro
is looking forward to working closely with Dr. Bunn and the other
members of our new Oncology Advisory Board as we advance our new
product candidates into the clinic. We welcome their close scrutiny
and counsel," commented Leonard P. Shaykin, Chairman and Chief
Executive Officer of NaPro. Brief backgrounds of the members of the
Oncology Advisory Board are given below: Paul A. Bunn, Jr., M.D.
(Chairman): Dr. Bunn is the Director of the University of Colorado
Cancer Center, previous president (2002-2003) of the American
Society of Clinical Oncology (ASCO), and former chairman of the
Oncology Drugs Advisory Committee (ODAC) of the FDA. Dr. Bunn is an
authority in the field of clinical oncology with a research
specialty in lung cancer. Dr. Bunn received his M.D. from Cornell
University Medical College. S. Gail Eckhardt, M.D.: Dr. Eckhardt is
a Professor of Medicine and the Director of the Developmental
Therapeutics and GI Malignancies Programs at the University of
Colorado Health Science Center in Denver. She is a member of the
ASCO Board of Directors and ASCO Publications Committee. She
previously worked as an Associate Director of Clinical Research,
Cancer Therapy and Research Center at the Institute for Drug
Development in San Antonio, Texas. Dr. Eckhardt received her M.D.
from the University of Texas Medical Branch in Galveston. Eric K.
Rowinsky, M.D.: Dr. Rowinsky is the Director of the Institute for
Drug Development, Cancer Therapy and Research Center and Clinical
Professor of Medicine at the University of Texas Health Science
Center at San Antonio. He serves as the Editor-in-Chief of
Investigational New Drugs and as an Associate Editor for various
publications, including Cancer Research. Dr. Rowinsky also serves
on the NCI Board of Scientific Counselors. He is actively involved
in preclinical and clinical research in anticancer drug development
and has played pivotal roles in the regulatory approval of a large
number of contemporary anticancer therapeutics such as Taxotere(R).
Dr. Rowinsky received his M.D. from the Vanderbilt School of
Medicine. Daniel D. Von Hoff, M.D.: Dr. Von Hoff is Professor of
Medicine, Pathology, Molecular and Cellular Biology and the
Director of the Arizona Health Sciences Center's Cancer
Therapeutics Program. He is, also, Director of Translational
Research at the Translational Genomics Research Institute (TGen).
He is Chief Scientific Officer for US Oncology, Inc. and a founder
and board member of ILEX Oncology, Inc. Dr. Von Hoff has been
involved in the initial development of many anticancer agents,
including paclitaxel, docetaxel, gemcitabine and CPT-11. He is
currently concentrating on the development of molecularly targeted
therapies. Dr. Von Hoff received his M.D. from Columbia University.
About NaPro BioTherapeutics NaPro BioTherapeutics, Inc. is a
pharmaceutical company focused on the development of therapies for
the treatment of cancer and hereditary disease. For more
information about NaPro and its technologies, visit NaPro's web
site at http://www.naprobio.com/. Forward Looking Statements The
statements in this press release that are not historical facts are
forward-looking statements that represent management's beliefs and
assumptions as of the date of the press release, based on currently
available information. Forward-looking statements can be identified
by the use of words such as "believes," "intends," "estimates,"
"may," "will," "should," "anticipates," "expected" or comparable
terminology or by discussions of strategy, and include statements
regarding the Company's advancing new product candidates into the
clinic and the nature of scrutiny and counsel by the Oncology
Advisory Board. Although the Company believes that the expectations
reflected in such forward-looking statements are reasonable, it
cannot assure that these expectations will prove to be correct.
Such statements involve risks and uncertainties including those
factors identified under the captions "Risk Factors," "Special Note
Regarding Forward Looking Statements" or "Cautionary Note Regarding
Forward Looking Statements" in the Company's documents filed from
time to time with the SEC, including the Company's Annual Report on
Form 10-K for the year ending December 31, 2003 filed with the SEC
on March 11, 2004. Should one or more of these risks materialize
(or the consequences of such a development worsen), or should the
underlying assumptions prove incorrect, actual results could differ
materially from those forecasted or expected. The Company disclaims
any intention or obligation to update publicly or revise such
statements whether as a result of new information, future events or
otherwise. For further information, please contact L. Robert Cohen,
Vice President, Investor Relations of NaPro BioTherapeutics, Inc.,
+1-212-218-8715. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT:
L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., +1-212-218-8715; or investors, Lilian Stern
of Stern Investor Relations, Inc., +1-212-362-1200, or media, Peter
Steinerman, +1-516-374-3031, both for NaPro BioTherapeutics, Inc.
Web site: http://www.naprobio.com/
Copyright
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Sep 2023 to Sep 2024